Human T Lymphoid Progenitor (HTLP) injection

DRUG2 trials

Sponsors

Assistance Publique - Hôpitaux de Paris

Conditions

Any Type of Severe Combined Immunodeficiency (SCID)Hematologic MalignancyPartial HLA Incompatible Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)Pediatric Patients

Phase 1

Safety and Efficacy Study of Human T Lymphoid Progenitor (HTLP) Injection After Partially HLA Compatible Allogeneic Hematopoietic Stem Cell Transplantation in SCID Patients

CompletedNCT03879876

Assistance Publique - Hôpitaux de ParisAny Type of Severe Combined Immunodeficiency (SCID), Partial HLA Incompatible Allogeneic Hematopoietic Stem Cell Transplantation (HSCT), Pediatric Patients

Start: 2020-05-13End: 2024-04-24Updated: 2026-05-20

Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)

RecruitingNCT04707300

Assistance Publique - Hôpitaux de ParisHematologic Malignancy

Start: 2022-02-16End: 2029-02-01Target: 10Updated: 2026-08-12

Related Papers

Ex Vivo Generation of Human T-Cell Progenitors from Cord Blood CD34+ Cells Can Accelerate Immune Reconstitution after Umbilical Cord Blood Transplantation in Adult Patient with Hematologic Malignancies

Blood2024-11-05

Rapid and Safe T Cell Immune Reconstitution By T Cell Progenitor Injection Following Haploidentical Transplantation for Severe Combined Immunodeficiency (SCID)

Blood2021-11-05